ASH 2017: Highlights on Non-Hodgkin Lymphoma

Speaker: Michele Ghielmini

Reporting from ASH 2017 on Non-Hodgkin Lymphoma, Michele Ghielmini highlights the results of the NCI 9177 phase II study on DA-EPOCH-R in Burkitt's Lymphoma and studies presenting data on CAR-T cell therapy in relapsed/refractory DLBCL.

Relapsed/refractory Burkitt's Lymphoma is curable but treatment is aggressive. In NCI 9177, negative interim PET after 2 cycles allowed treatment to be stopped after only 1 additional cycle. Patients with relapsed/refractory DLBCL are a very poor prognostic group, however approx. 50% of patients were seen to respond to CAR-T cell therapy with approx. one third still responding at 6 months: this represents the most promising treatment option for these patients. These studies underline the expectation that chemotherapy will not make further progress in lymphoma and that integration of biological, targeted and immuno-therapies in combination with chemotherapy will lead to further improved survival and quality of life.


Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R
CAR-T celles to treat Relapse/Refractory DLBCL:
577: Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
578: Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
581: High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort